

# Immunoregulatory Kinases

## R428

AXL kinase inhibitor. Suppressed myeloid cell activation and enhanced PD-1 blockade therapy.<sup>1,2</sup>

**Product No: 10-4676** 5 mg/ 25 mg/

## Pexidartinib

Dual inhibitor of CSF1R and c-KIT. Inhibits suppression of antitumor immunity<sup>3</sup> and increases efficacy of ACT<sup>4</sup>, anti-PD-1<sup>5</sup>, and DC immunotherapy<sup>6</sup>.

**Product No: 10-4829** 5 mg/ 25 mg/

## Idelalisib

Selective PI3K $\delta$  inhibitor. Increases CD8 T cells via attenuation of regulatory T cells.<sup>7</sup>

**Product No: 10-4820** 10 mg/ 50 mg/

## IPI-549

Selective PI3K $\gamma$  inhibitor. Promotes cytotoxic T cell-mediated tumor regression. Anti-PD-1 checkpoint blockade resistance was overcome when combined with IPI-549.<sup>8</sup>

**Product No: 10-4827** 5 mg/ 25 mg/

## Duvelisib

Dual PI3K $\delta/\gamma$  inhibitor. Enhanced PD-L1 efficacy in T cell-inflamed tumor models via suppression of myeloid-derived suppressor cells.<sup>9</sup>

**Product No: 10-4788** 5 mg/ 25 mg/

## Defactinib

FAK inhibitor. Shows synergistic activity in combination with checkpoint blockade.<sup>10,11</sup>

**Product No: 10-4828** 5 mg/ 25 mg/

## Galunisertib

TGF- $\beta$  kinase inhibitor. Reversed TGF- $\beta$  and Treg mediated T cell suppression and enhanced PD-L1 blockade therapy.<sup>12</sup>

**Product No: 10-4110** 5 mg/ 25 mg/

## GSK8612

SHP2 phosphatase inhibitor. SHP2 mediates PD-1 and BTLA immune checkpoint pathways.<sup>13</sup>

**Product No: 10-4693** 5 mg/ 25 mg/

## Trametinib

MEK Inhibitor. Inhibits expansion of myeloid-derived suppressor cells.<sup>14,15</sup>

**Product No: 10-4759** 10 mg/ 50 mg/

## Axitinib

VEGFR inhibitor. Decreases myeloid-derived suppressor cell by downregulating STAT3<sup>16,17</sup>

**Product No: 10-2118** 10 mg/ 50 mg/

## Palbociclib


CDK4/6 inhibitor. Suppressed Treg cells and enhanced tumor antigen presentation.<sup>18</sup>

**Product No: 10-4760** 5 mg/ 25 mg/


## Deucravacitinib

Potent and selective allosteric inhibitor of TYK2. Blocked signaling and functional responses in human T<sub>H</sub>17, T<sub>H</sub>1, B cells, and myeloid cells.<sup>19</sup>


**Product No: 10-4756** 5 mg/ 25 mg/



**Pexidartinib**



**Duvelisib**



**Galunisertib**

## REFERENCES

1. Guo, *et al.* (2017), *Oncotarget* **8** 89761
2. Ludwig, *et al.* (2018), *Cancer Res.* **78** 246
3. DeNardo, *et al.* (2011), *Cancer Disc.* **1** 54
4. Mok *et al.* (2014) *Cancer Res.* **74** 15
5. Shi *et al.* (2019), *Mol. Ther.* **27** 244
6. Dammeijer *et al.* (2017), *Cancer Immunol. Res.* **5** 535
7. Ahmad *et al.* (2017), *Cancer Res.* **77** 1892
8. De Henau *et al.* (2016), *Nature* **539** 443
9. Davis *et al.* (2017), *Cancer Res.* **77** 2607
10. Ring, *et al.* (2015), *J. Immunother. Cancer* **3** 354
11. Jiang *et al.* (2016), *Nat. Med.* **22** 851
12. Holgaard *et al.* (2018), *J. Immunother. Cancer* **6** 47
13. Thomson *et al.* (2019), *ACS Med. Chem. Lett.* **10** 780
14. Allegrezza *et al.* (2016), *Cancer Res.* **76** 6253
15. Vella *et al.* (2014), *Cancer Immunol. Res.* **2** 351
16. Yuan *et al.* (2015), *Biomed. Pharmacother.* **68** 751
17. Zhang *et al.* (2014), *Anticancer Drugs* **25** 204
18. Goel *et al.* (2017), *Nature* **548** 471
19. Burke *et al.* (2019), *Sci. Transl. Med.* **11** eaaw1736